Across TCGA pan-cancer cohorts, SLC9A6 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SLC9A6 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SLC9A6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SLC9A6 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and UCEC show a favorable association.

CCRCC, LUAD, and UCEC are the cancer types where SLC9A6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.860	0.611	.001	30	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	8	view →
UCEC	OS	Median	All	0.982	0.914	.035	4	view →
LSCC	OS	Quartile	III,IV	1.000	0.548	.049	2	view →
GBM	DFS	Tertile	All	0.864	0.742	.042	2	view →
HNSC	OS	Tertile	III,IV	0.770	0.557	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: SLC9A6 tumor-vs-normal RNA expression · all SLC9A6 data types